ReviewInternational journal of pharmaceutics: X2025
Comparative evaluation of ternary amorphous solid dispersions: Identifying optimal excipient systems for enhancing drug solubility.
Review in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The limited aqueous solubility of numerous active pharmaceutical ingredients (APIs) remains a major barrier to achieving optimal oral bioavailability, therapeutic efficacy, and clinical translation. Amorphous solid dispersion (ASD) systems have emerged as a leading strategy to overcome these biopharmaceutical limitations, with ternary ASDs offering greater formulation flexibility and performance enhancement through the synergistic inclusion of functional third components. Aims: This review aims to systematically explore and critically analyze the formulation strategies, comparative outcomes, and molecular mechanisms underlying ternary ASDs-specifically Drug:Polymer:Polymer, Drug:Polymer:Surfactant, Drug:Polymer:Excipient, and Drug:Drug:Polymer systems-in improving solubility, dissolution, stability, and pharmacokinetic performance
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.